Lymphoma Treatment Market To Reach $63 Billion by 2035

Global Lymphoma Treatment Market was valued at $28 billion in 2025 and is projected to reach $63 billion by 2035, growing at a CAGR of 8.50% during the forecast period (2026–2035) driven by rising cancer prevalence, advancements in targeted therapies, and increasing healthcare investments. A key macro driver accelerating market growth is the rising global cancer burden. According to the World Health Organisation, cancer accounted for nearly 10 million deaths globally in 2022, making it one of the leading causes of mortality worldwide. Additionally, the International Agency for Research on Cancer estimates that global cancer cases are expected to rise to over 35 million by 2050, reflecting a significant increase in oncology treatment demand, including lymphoma therapies.

Browse the full report description of “Lymphoma Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation, CAR-T Cell Therapy), By Lymphoma Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Route of Administration (Intravenous (IV), Oral, Subcutaneous), By Therapy Line (First-Line Therapy, Second-Line Therapy, Third-Line & Salvage Therapy), By End-User (Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Research Institutes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Technology Platform (Cell Therapy, Biologics, Small Molecule Drugs, Gene Therapy), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/lymphoma-treatment-market

From an end-user perspective, hospitals and speciality cancer centres dominate the market, supported by increasing oncology treatment volumes. According to the European Federation of Pharmaceutical Industries and Associations, oncology accounts for a significant share of pharmaceutical R&D investments, with over 40% of medicines in development targeting cancer-related conditions. This surge in R&D directly supports innovation in lymphoma treatments such as CAR-T cell therapies and immunotherapies. Among the segments, Immunotherapy and CAR-T Cell Therapy are witnessing the fastest growth due to their targeted mechanism of action and improved patient outcomes compared to traditional chemotherapy. The increasing adoption of biologics and cell-based therapies is further enhancing treatment efficacy, especially in relapsed and refractory lymphoma cases.

Recent developments highlight the competitive intensity and innovation in the market:

• In March 2026, Novartis agrees to acquire a pan-mutant-selective PI3K? inhibitor, strengthening its breast cancer pipeline.
• In March 2026, Bristol Myers Squibb’s sotyktu® (deucravacitinib) for the treatment of adults with active psoriatic arthritis gets approved by the U.S. FDA.
• In May 2025, Roche Holding AG is expanding its lymphoma portfolio with next-generation immunotherapies.

Additionally, several companies are investing in gene therapy platforms and precision oncology solutions, aiming to personalise lymphoma treatment and improve survival rates.

Geographically, North America dominates the market due to strong healthcare infrastructure and high adoption of advanced therapies, while Asia-Pacific is expected to register the fastest growth due to increasing healthcare expenditure and improving cancer diagnosis rates.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Treatment Type
  • Lymphoma Type
  • Route of Administration
  • Therapy Line
  • End-User
  • Distribution Channel
  • Technology Platform
• Regions Covered –
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Roche Holding AG, Novartis AG, Bristol Myers Squibb, Kite Pharma, Inc., AbbVie Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lymphoma Treatment Market Report Segment

• By Treatment Type
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Stem Cell Transplantation
  • CAR-T Cell Therapy
• By Lymphoma Type
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
• By Route of Administration
  • Intravenous (IV)
  • Oral
  • Subcutaneous
• By Therapy Line
  • First-Line Therapy
  • Second-Line Therapy
  • Third-Line & Salvage Therapy
• By End-User
  • Hospitals
  • Speciality Cancer Centres
  • Ambulatory Surgical Centres
  • Research Institutes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Technology Platform
  • Cell Therapy
  • Biologics
  • Small Molecule Drugs
  • Gene Therapy

Global Lymphoma Treatment Market Report Segment by Region

• North America
• United States
  • Canada
• Europe
• UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
• Asia-Pacific
• China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific
• Rest of the World
• Latin America
  • Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lymphoma-treatment-market